Bovine thymus extract put to the test in healthy volunteers
NCT ID NCT06795945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a supplement made from cow thymus (Thymus Nuclear Extract) is safe for healthy adults. Researchers gave 80 men and women three different doses or a placebo and monitored their vital signs, blood work, and any side effects. The goal was simply to check safety and tolerability, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male and female participants who are between 18 - 65 years of age (inclusive). 2. In good general health (i.e., no uncontrolled diseases or conditions) as deemed by the investigator and are able to consume the study product. 3. Have a body mass index (BMI) range of 18.5 - 29.9 kg/m2 (inclusive). 4. Agree to follow the restrictions on concomitant treatments as listed. 5. Agree to use acceptable contraceptive methods as listed. 6. Willing and able to agree to the requirements of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures. 7. Agree to the dosage instructions including the oral consumption of 8 tablets twice daily. Exclusion Criteria: 1. Individuals who are lactating, pregnant or planning to become pregnant during the study, or demonstrates a positive pregnancy test at Visit 2. 2. Have a known sensitivity, intolerability, or allergy (especially to bovine products) to any of the study products or their excipients. 3. Have Type I diabetes, uncontrolled Type II diabetes, uncontrolled high blood pressure (≥140 systolic or ≥90 diastolic mmHg), or uncontrolled thyroid disease ("uncontrolled" defined as being unmedicated, have an unstable use of medication within 3 months prior to screening, or have a stable use of medication for 3 months but still have uncontrolled conditions). 4. Have a chronic inflammatory condition (e.g., rheumatoid arthritis, lupus, or multiple-sclerosis). 5. Have a neurological disorder which may impact cognitive testing (e.g., traumatic brain injury, epilepsy, neurodegenerative diseases). 6. Have received an organ transplant or other forms of allografts or xenografts. 7. Participants with sleep disorders (e.g., insomnia, sleep apnea, restless legs syndrome, narcolepsy, or any other condition that significantly affects sleep quality and duration) 8. Have medical condition(s) known to interfere with absorption, distribution, metabolism, or excretion of the study product (e.g., Crohn's disease, short bowel, acute or chronic pancreatitis, or pancreatic insufficiency). 9. Have a history of heart/cardiovascular disease, renal disease (dialysis or renal failure), hepatic impairment/disease, immune disorders and/or immunocompromised (i.e., HIV/AIDS). 10. Have a history of cancer (except localized skin cancer without metastases or in situ cervical cancer), unless recovery occurred more than 5 years before the screening visit. 11. Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.). 12. Reports a clinically significant illness during the 28 days before the first dose of study product. 13. Major surgery in 3 months prior to screening or planned major surgery during the study. 14. Have a history of alcohol or substance abuse in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program) or use that in the opinion of the investigator may be of a concern for the study. 15. Current enrollment or past participation in another study with any product(s) with at least one active ingredient within 28 days before first dose of study product or longer, if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study. 16. Any other medical condition/situation or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to participate in the study or its measures or pose a significant risk to the participant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Immunology are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Model Research Center
Tampa, Florida, 33615, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.